Epi Biotech Co., Ltd.
KKRX:44644020,000.00
KRW
+1,000.00
(+5.26%)
ISIN
KR7446440000
Return %
Stock
S&P 500
1Y
22.70
14.39
3Y
69.49
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jong-Hyuk Sung
- Full Time Employees
- 23
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Inchon South Korea
- IPO Date
- Jul 31, 2023
- Website
- epibiotech.com
- Similar Companies
- Business
- Epi Biotech Co., Ltd. is a South Korea-based clinical-stage biopharmaceutical company that specializes in the research, development, and commercialization of therapeutics for alopecia and hair loss disorders, regenerative cell therapies, and contract development and manufacturing services. Founded in 2015 and headquartered in Incheon, South Korea, the company operates research laboratories and Good Manufacturing Practice (GMP) cell production facilities within the Songdo bio-cluster, serving institutional researchers, healthcare providers, and consumer healthcare markets primarily in South Korea and across the Asia-Pacific region. The company provides a diversified portfolio of therapeutic candidates, discovery platforms, and commercial bio-cosmetics, encompassing: EPI-001, an autologous dermal papilla cell therapy designed for the treatment of androgenetic alopecia; EPI-008, an allogeneic gene-edited cell therapy platform developed for off-the-shelf regenerative hair regrowth; EPI-005, a recombinant protein and biologics-based candidate formulated to activate hair follicle regeneration pathways; EPI-003 and EPI-004, synthetic peptide-based therapeutics engineered to stimulate hair follicle stem cells; proprietary 3D hair follicle organoid screening platforms for high-throughput in vitro efficacy testing and drug discovery; specialized contract development and manufacturing organization (CDMO) services for cell and gene therapy developers; and functional derma-cosmeceutical scalp care formulations, including topical hair growth ampoules, peptide tonics, and cell-conditioned media solutions. In recent developments, Epi Biotech Co., Ltd. listed its shares on the Korea Exchange (KRX: 446440) on the KONEX market as part of its strategic roadmap toward a technology-specialized transfer listing to KOSDAQ. The company has also expanded its commercial operations by activating its dedicated GMP manufacturing facility in Songdo to provide third-party CDMO and cell-banking services, while entering into strategic research partnerships and joint development agreements with domestic pharmaceutical and aesthetic healthcare companies to develop transdermal delivery formulations and advance regulatory clinical trials for its primary cell therapy pipeline.